Pulmonology Book

http://www.fpnotebook.com/

Leukotriene Receptor Antagonist

Aka: Leukotriene Receptor Antagonist, Leukotriene Antagonist, Leukotriene Synthesis Inhibitor, Accolate, Zafirlukast, Montelukast, Singulair, Zileuton, Zyflo
  1. Preparations
    1. Zafirlukast (Accolate)
    2. Montelukast (Singulair)
    3. Zileuton (Zyflo)
  2. Mechanism
    1. Attenuates bronchoconstriction and inflammation
    2. Leukotriene Receptor Antagonists
      1. Zafirlukast (Accolate)
      2. Montelukast (Singulair)
    3. Leukotriene Synthesis Inhibitor
      1. Zileuton (Zyflo)
  3. Indication: Adjunctive in Asthma and Allergic Rhinitis
    1. Moderate Persistent Asthma
    2. Severe Persistent Asthma
    3. Moderate Chronic Obstructive Pulmonary Disease
    4. Aspirin-induced Asthma
    5. Exercise-Induced Bronchospasm
    6. Allergic Rhinitis
  4. Dosing: Zafirlukast (Accolate)
    1. Leukotriene Receptor Antagonist
    2. Avoid at mealtime
      1. Take 1 hour before or 2 hours after meals
    3. Dose
      1. Age >11 years old: 20 mg orally twice daily
      2. Child 7-11 years old: 10 mg orally twice daily
  5. Dosing: Montelukast (Singulair)
    1. Leukotriene Receptor Antagonist
    2. Dose
      1. Adults: 10 mg orally at bedtime
      2. Child age 6 to 14 years: 5 mg orally at bedtime
      3. Child age 2-5 years: 4 mg orally at bedtime
  6. Dosing: Zileuton (Zyflo)
    1. Leukotriene Synthesis Inhibitor
    2. Indicated only in age 12 and over
    3. Dosing
      1. Dose: 600 mg orally four times daily
    4. Risks
      1. Hepatotoxicity in 5% (Monitor liver enzymes q3 months)
      2. Drug Interactions: Warfarin, Theophylline, Propranolol
      3. Expensive ($273 per month)
  7. Efficacy
    1. Modestly effective for maintenance management
    2. Inhaled Steroids are preferred over leukotriene agents
    3. Used as adjunctive therapy in Asthma
    4. Benefit may be limited to patients with the 5-LO and LTC4 polymorphisms
      1. Sampson (2004) RT J Respir Care Practitioners 17:30-2 [PubMed]
      2. Wechsler (2005) Am J Respir Crit Care Med 172(1): 12-8 [PubMed]
  8. Adverse Effects
    1. Multiple P450 Drug Interactions
      1. Potentiates Warfarin
      2. Potentiates Theophylline
      3. Potentiates Propranolol
    2. Some association with Churg-Strauss Syndrome
      1. Systemic Eosinophilic Vasculitis
      2. Vasculitic rash
      3. Pulmonary and cardiac conditions
    3. Hepatotoxicity with Zileuton (Zyflo)
  9. Cost
    1. Among most expensive agents in Asthma
    2. Accolate and Singulair: $90-100 per month
    3. Zyflo: $270 per month
  10. References
    1. (1996) Med Lett Drugs Ther 38:111-2 [PubMed]
    2. (2000) Med Lett Drugs Ther 42:22-3 [PubMed]
    3. Scow (2007) Am Fam Physician 75:65-70 [PubMed]
    4. Wilson (2001) Chest 119:2021-6 [PubMed]
Medication Costs
zafirlukast (on 2/22/2017 at Medicaid.Gov Pharmacy Drug pricing)
ZAFIRLUKAST 10 MG TABLET Generic $1.31 each
ZAFIRLUKAST 20 MG TABLET Generic $1.30 each
montelukast (on 5/17/2017 at Medicaid.Gov Pharmacy Drug pricing)
MONTELUKAST SOD 10 MG TABLET Generic $0.10 each
MONTELUKAST SOD 4 MG GRANULES Generic $3.25 each
MONTELUKAST SOD 4 MG TAB CHEW Generic $0.18 each
MONTELUKAST SOD 5 MG TAB CHEW Generic $0.17 each
singulair (on 6/8/2017 at Medicaid.Gov Pharmacy Drug pricing)
SINGULAIR 10 MG TABLET Generic $0.10 each
SINGULAIR 4 MG GRANULES Generic $3.25 each
SINGULAIR 4 MG TABLET CHEW Generic $0.18 each
SINGULAIR 5 MG TABLET CHEW Generic $0.17 each
zyflo (on 12/1/2016 at Medicaid.Gov Pharmacy Drug pricing)
ZYFLO CR 600 MG TABLET $28.51 each
FPNotebook does not benefit financially from showing this medication data or their pharmacy links. This information is provided only to help medical providers and their patients see relative costs. Insurance plans negotiate lower medication prices with suppliers. Prices shown here are out of pocket, non-negotiated rates. See Needy Meds for financial assistance information.

zileuton (C0081408)

Definition (NCI_NCI-GLOSS) A substance that is used to prevent asthma symptoms and that is being studied in the prevention of lung cancer. It belongs to the family of drugs called leukotriene blockers.
Definition (NCI) A synthetic derivative of hydroxyurea with antiasthmatic properties. The leukotriene inhibitor zileuton blocks 5-lipoxygenase, which catalyzes the formation of leukotrienes from arachidonic acid; causes bronchodilation; decreases bronchial mucous secretion and edema; and may prevent or decrease the symptoms of asthma. (NCI04)
Definition (PDQ) A synthetic derivative of hydroxyurea with antiasthmatic properties. The leukotriene inhibitor zileuton blocks 5-lipoxygenase, which catalyzes the formation of leukotrienes from arachidonic acid; causes bronchodilation; decreases bronchial mucous secretion and edema; and may prevent or decrease the symptoms of asthma. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=285649&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=285649&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26667" NCI Thesaurus)
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C063449
SnomedCT 386180009, 108617005
English N-(1-benzo(b)thien-2-ylethyl)-N-hydroxyurea, zileuton, (+-)-N-Hydroxy-N-(1-benzo[b]thien-2-ylethyl)-urea, N-(1-Benzo[b]thien-2-ylethyl)-N-hydroxyurea, zileuton (Zyflo), zileuton (medication), ZILEUTON, zileuton [Chemical/Ingredient], Zileuton (product), Zileuton (substance), Zileuton, ZLT
Spanish zileutona, zileutón, zileutón (producto), zileutona (sustancia), zileutona (producto), zileutón (sustancia)
Sources
Derived from the NIH UMLS (Unified Medical Language System)


montelukast (C0298130)

Definition (NCI_NCI-GLOSS) The active ingredient in a drug used to treat symptoms of asthma, such as trouble breathing, tight chest, wheezing, coughing, and runny nose. Montelukast blocks the action of a substance that causes airways in the lungs to narrow and causes other symptoms of asthma. It is a type of leukotriene receptor antagonist and a type of antiasthmatic agent.
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C093875
SnomedCT 320883008, 108619008, 373734003, 373728005
LNC LP171622-6
English montelukast (medication), montelukast, montelukast [Chemical/Ingredient], Montelukast agent, Montelukast (product), Montelukast agent (substance), MONTELUKAST, Montelukast product, Montelukast, Montelukast (substance), Montelukast product (product), Montelukast product (substance)
Spanish montelucast, producto (producto), montelukast (producto), montelucast, producto, agente con montelukast (sustancia), agente con montelukast, montelucast, producto (sustancia), montelukast (sustancia), montelukast
Sources
Derived from the NIH UMLS (Unified Medical Language System)


zafirlukast (C0378466)

Definition (NCI_NCI-GLOSS) A drug used to prevent and treat symptoms of asthma. It blocks substances that cause inflammation in the lungs. It is a type of antiasthmatic agent and a leukotriene receptor antagonist.
Definition (NCI) A toyl compound with anti-asthmatic property. Zafirlukast selectively and competitively binds and blocks the cysteinyl leukotriene 1 receptor , thereby preventing potent proinflammatory mediators leukotriene C4, D4 and E4 from binding. This prevents leukotriene-mediated actions, including enhanced migration of eosinophils and neutrophils, increased adhesion of leukocytes, increased monocyte and neutrophil aggregation, increased airway edema, inflammation, capillary permeability and bronchoconstriction.
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C062735
SnomedCT 320888004, 108614003, 386880006
English 4-(5-cyclopentyloxycarbonylamino-2-methylindol-3-yl-methyl)-3-methoxy-N-O-tolylsulfonylbenzamide, zafirlukast, Carbamic Acid,(3-((2-methoxy-4-((((2-methylphenyl)sulfonyl)amino)carbonyl)phenyl)methyl)-1-methyl-1H-indol-5-yl)-, Cyclopentyl Ester, Cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate, zafirlukast (medication), zafirlukast [Chemical/Ingredient], ZAFIRLUKAST, Zafirlukast, Zafirlukast (product), Zafirlukast (substance)
Spanish zafirlukast (producto), zafirlukast (sustancia), zafirlukast
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Accolate (C0526502)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C062735
English Accolate, accolate, AstraZeneca brand of zafirlukast, Zeneca brand of zafirkulast
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Singulair (C0595724)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C093875
English Singulair, singulair, Cahill May Roberts brand of montelukast sodium, Merck Frosst brand of montelukast sodium, Merck Sharp & Dohme brand of montelukast sodium, Merck brand of montelukast sodium
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Leukotriene Antagonists (C0595726)

Definition (MSH) A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level.
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH D020024
SnomedCT 108616001, 372517002
Swedish Leukotrienblockerare
English ANTAG LEUKOTRIENE, LEUKOTRIENE ANTAG, RECEPT ANTAG LEUKOTRIENE, LEUKOTRIENE RECEPT ANTAG, Leukotriene receptor antagnist, Antagonists, Leukotriene, Antagonists, Leukotriene Receptor, Leukotriene Receptor Antagonists, Receptor Antagonists, Leukotriene, leukotriene inhibitors (medication), leukotriene inhibitors, Leukotriene Antagonists, inhibitors leukotriene receptor, leukotriene antagonist, leukotriene antagonists, leukotriene receptor antagonist, leukotriene receptor antagonists, Leukotriene receptor antagonist, Leukotriene receptor inhibitor (product), Leukotriene receptor inhibitor (substance), Leukotriene receptor inhibitor, Antileukotrienes
Czech leukotrieny - antagonisté, receptory leukotrienů - antagonisté
Finnish Leukotrieeniantagonistit
Russian LEIKOTRIENA ANTAGONISTY, RETSEPTOROV LEIKOTRIENA ANTAGONISTY, ЛЕЙКОТРИЕНА АНТАГОНИСТЫ, РЕЦЕПТОРОВ ЛЕЙКОТРИЕНА АНТАГОНИСТЫ
Polish Antagoniści receptorów leukotrienowych, Antagoniści leukotrienów, Leki antyleukotrienowe
Japanese ロイコトリエン拮抗剤, ロイコトリエンアンタゴニスト, ロイコトリエンレセプターアンタゴニスト, ロイコトリエン受容体アンタゴニスト, ロイコトリエン受容体拮抗剤, ロイコトリエン受容体拮抗物質, ロイコトリエン受容体拮抗薬, ロイコトリエン拮抗物質, ロイコトリエン拮抗薬
Norwegian Leukotrienantagonister, Leukotrienhemmere, Leukotrienreseptorantagonister
Spanish inhibidor del receptor de leucotrieno (sustancia), inhibidor del receptor de leucotrienos (producto), inhibidor del receptor de leucotrienos (sustancia), inhibidor del receptor de leucotrienos, inhibidor del receptor de leucotrieno, Antagonistas de Leucotrieno, Antagonistas de Receptor de Leucotrieno
German Leukotrien-Antagonisten, Leukotrien-Rezeptor-Antagonisten
Italian Antagonisti dei leucotrieni
Portuguese Antagonistas de Leucotrienos, Antagonistas dos Receptores de Leucotrienos
French Antagonistes des leucotriènes, Antagonistes des récepteurs aux leucotriènes, Antagonistes des récepteurs des leucotriènes
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Zyflo (C0724508)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C063449
English Zyflo, zyflo, Abbott brand of zileuton
Sources
Derived from the NIH UMLS (Unified Medical Language System)


You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree